TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · IEX Real-Time Price · USD
148.97
-1.22 (-0.81%)
At close: Jul 2, 2024, 4:00 PM
149.80
+0.83 (0.56%)
After-hours: Jul 2, 2024, 7:58 PM EDT
TransMedics Group Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for TransMedics Group stock have an average target of 122.5, with a low estimate of 70 and a high estimate of 175. The average target predicts a decrease of -17.77% from the current stock price of 148.97.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for TMDX stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 3 | 2 |
| Buy | 3 | 4 | 5 | 5 | 4 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Maintains $130 → $175 | Strong Buy | Maintains | $130 → $175 | +17.47% | Jun 7, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $151 | Buy | Initiates | $151 | +1.36% | Jun 4, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $102 → $117 | Strong Buy | Maintains | $102 → $117 | -21.46% | May 1, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $100 → $130 | Strong Buy | Maintains | $100 → $130 | -12.73% | May 1, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $105 → $127 | Buy | Maintains | $105 → $127 | -14.75% | May 1, 2024 |
Financial Forecast
Revenue This Year
409.46M
from 241.62M
Increased by 69.46%
Revenue Next Year
538.45M
from 409.46M
Increased by 31.50%
EPS This Year
0.82
from -0.77
EPS Next Year
1.14
from 0.82
Increased by 39.47%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 441.6M | 597.1M | 730.8M | 906.2M | 1.1B |
| Avg | 409.5M | 538.5M | 667.4M | 849.0M | 1.0B |
| Low | 387.1M | 490.0M | 588.0M | 800.2M | 940.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 82.8% | 45.8% | 35.7% | 35.8% | 26.6% |
| Avg | 69.5% | 31.5% | 23.9% | 27.2% | 19.2% |
| Low | 60.2% | 19.7% | 9.2% | 19.9% | 10.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.31 | 2.07 | 2.94 | 4.11 | 5.23 |
| Avg | 0.82 | 1.14 | 2.41 | 3.99 | 5.08 |
| Low | -0.05 | -0.71 | 1.76 | 3.83 | 4.88 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 153.1% | 157.9% | 70.6% | 31.1% |
| Avg | - | 39.5% | 111.2% | 65.7% | 27.4% |
| Low | - | - | 54.8% | 59.2% | 22.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.